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Abstract
Background: Type 2 Diabetes Mellitus (T2DM) and diabetic symmetrical polyneuropathy (DSP) impact multiple
modalities of sensation including light touch, temperature, position sense and vibration perception. No study to
date has examined the mechanosensitivity of peripheral nerves during limb movement in this population. The
objective was to determine the unique effects T2DM and DSP have on nerve mechanosensitivity in the lower
extremity.
Methods: This cross-sectional study included 43 people with T2DM. Straight leg raise neurodynamic tests were
performed with ankle plantar flexion (PF/SLR) and dorsiflexion (DF/SLR). Hip flexion range of motion (ROM), lower
extremity muscle activity and symptom profile, intensity and location were measured at rest, first onset of
symptoms (P1) and maximally tolerated symptoms (P2).
Results: The addition of ankle dorsiflexion during SLR testing reduced the hip flexion ROM by 4.3° ± 6.5° at P1 and
by 5.4° ± 4.9° at P2. Individuals in the T2DM group with signs of severe DSP (n = 9) had no difference in hip
flexion ROM between PF/SLR and DF/SLR at P1 (1.4° ± 4.2°; paired t-test p = 0.34) or P2 (0.9° ± 2.5°; paired t-test
p = 0.31). Movement induced muscle activity was absent during SLR with the exception of the tibialis anterior
during DF/SLR testing. Increases in symptom intensity during SLR testing were similar for both PF/SLR and DF/SLR.
The addition of ankle dorsiflexion induced more frequent posterior leg symptoms when taken to P2.
Conclusions: Consistent with previous recommendations in the literature, P1 is an appropriate test end point for
SLR neurodynamic testing in people with T2DM. However, our findings suggest that people with T2DM and severe
DSP have limited responses to SLR neurodynamic testing, and thus may be at risk for harm from nerve overstretch
and the information gathered will be of limited clinical value.
Background
Diabetes mellitus (DM) is a group of metabolic disor-
ders that are characterized by hyperglycemia [1]. The
Center for Disease Control (CDC) estimated the mean
prevalence of DM in the United States (US) in 2005 was
7.0% [2]. Type 2 diabetes mellitus (T2DM) is the most
common form of diabetes and is estimated to represent
90-95% of those in the US with diabetes [2]. In 2002,
the total estimated direct and indirect costs of DM med-
ical care in the US was $132 billion [3].
Chronic hyperglycemia has adverse metabolic and vas-
cular consequences for the peripheral nervous system
[1,4]. Distal symmetrical polyneuropathy (DSP) is the
most common neural consequence of hyperglycemia
and is present in 30%-60% of people with T2DM
depending on the methodology for assessment [1,5,6].
DSP presents as distal, symmetrical sensory alterations
that begin in the feet and progress into the legs and
hands [1,5-8]. Multiple types of sensation are affected in
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any medium, provided the original work is properly cited.DSP including vibration sense [9,10], light touch sensa-
tion [6,8], position sense [5,8], temperature discrimina-
tion [5,7,8], as well as diminished ankle reflexes [5-8].
Pain can also be present [1,5-8]. Motor loss is usually
minor or sub-clinical until advanced stages of the dis-
ease [1,5-7]. The severity of DSP is related to the dura-
tion and severity of hyperglycemia [6,7].
Clinical neurodynamic tests are procedures designed
to assess the mechanosensitivity of the nervous system
through sequential limb movements [11-14]. Multiple
studies have examined the response of neural structures
in the lower extremity to a straight leg raise test (SLR)
in people with healthy nervous systems [12,13,15-17]. In
these studies, ankle dorsiflexion is most commonly used
to “sensitize” the SLR test by adding longitudinal loads
to the sciatic and tibial nerves. No study to date has
examined the mechanosensitivity of peripheral nerves to
the elongation and compression associated with limb
movement in people with T2DM. In fact, most studies
examining neurodynamic testing specifically exclude
people with T2DM [12,14,18-20]. Since T2DM and DSP
have been shown to affect multi-modal sensory, reflex
and motor systems in the distal lower extremities
[1,5-8], we expected to find a similar reduction in per-
ipheral nerve mechanosensitivity. The objective of this
study was to determine the unique effects of T2DM and
DSP severity on peripheral nerve mechanosensitivity in
the lower extremity to enhance our understanding of
appropriate activity guidelines and physical assessment
considerations for people with T2DM. We present the
unique impacts of T2DM and DSP on range of motion
changes, muscle activity, and symptoms during SLR
neurodynamic testing.
Methods
This cross sectional study included 43 people with
T2DM recruited from local medical and academic facil-
ities. Sample size was based on power calculations for a
multiple linear regression model with 5 predictor vari-
ables, alpha = 0.05, power of 0.8, and an effect size =
0.35. Exclusion criteria included low back or leg pain
lasting >3 consecutive days in the past 6 months, com-
plex regional pain syndrome, lumbar spine surgeries,
chemical dependence or alcohol abuse, a history of scia-
tica or trauma to the nerves of the lower extremity, or
chemotherapy in the past year. Participants had to meet
flexibility requirements of isolated hip flexion ≥90°, full
knee extension, ankle dorsiflexion ≥0° and plantar flex-
ion ≥30°. Institutional review boards at UCSF, SFSU and
the General Clinical Research Center’s Advisory Com-
mittee at UCSF approved the study and assured compli-
ance with the ethical treatment of human subjects.
Written informed consent was obtained from subjects
prior to testing. All subjects attended a single clinical
assessment session. One examiner (BB) performed all
physical examinations.
Clinical assessments
Questionnaires
Participants completed 1) a medical history question-
naire, 2) the Brief Pain Inventory - Short Form (BPI-SF)
[21], 3) the Michigan Neuropathy Screening Instrument
questionnaire (MNSIq), and 4) the Modified Baecke
Questionnaire (MBQ). The MNSIq has 15 questions
addressing symptoms associated with neuropathy [22].
The MBQ is a self-report questionnaire on physical
activity during work, recreation/sport, and leisure time
[23].
Vibration sensory testing
Vibration perception thresholds (VPT) were measured
bilaterally on the distal pad of the halluces using a 60-
Hz biothesiometer (Bio-Medical Instrument Company,
Newbury, OH). The halluces were tested in prone with
the leg supported in 90° knee flexion and neutral ankle.
The tip of the biothesiometer was balanced on the test-
ing site to ensure consistent contact pressure as
described previously [24,25]. The voltage was increased
at variable speeds to a maximum of 50 V then reduced
to 0 V position to avoid subject anticipation. The sub-
ject was instructed to report the first feeling of vibration
(VPT). Measurements were repeated twice on each limb
and averaged. A bilateral VPT average was calculated
(VPT-AVG).
Clinical neuropathy examinations
Two scoring instruments of composite physical exami-
nations were used as additional means of quantifying
severity of DSP [22]. First, the Michigan Neuropathy
Screening Instrument clinical examination (MNSIc) was
performed, which included visual inspection for foot
deformities or ulcerations, ankle deep tendon reflexes,
tuning fork vibration perception (128-Hz) and monofila-
ment sensory testing (10-gram) of the dorsal halluces
[22]. Scoring for each examination has been described
in detail [22,26,27]. Briefly, ankle reflexes were scored as
present, present with reinforcement or absent. Reinfor-
cement consisted of looking away from the testing side
and gripping hands and pulling apart. The subject’sp e r -
ception of tuning fork vibration cessation was scored as
present (<10-second discrepancy between subject and
tester), diminished (≥10-seconds discrepancy) or absent
(unable to feel). Monofilament testing was scored as
normal (≥8/10 correct responses), decreased (<8/10 cor-
rect responses), or absent (unable to feel).
Second, the Michigan Diabetic Neuropathy Score
(MDNS) clinical examination was performed, which
included Achilles, patellar, biceps brachii and triceps
brachii deep tendon reflexes, monofilament, tuning fork
vibration and sharp/dull sensation of the dorsal halluces
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ion and halluces extension. Scoring for each examina-
tion has been described in detail [22,26,27]. Reflexes,
vibration and monofilament sensation were scored iden-
tically to the MNSIc. Reinforcement for the upper extre-
mity reflexes consisted of looking away while pressing
the feet together and lightly clenching the jaw. Sharp/
dull sensation was scored as present (≥3/5 correct
responses) or absent (<3/5 correct responses). Muscle
strength was assessed with manual resistance and scored
according to the method of Feldman et al. as normal
strength, mild to moderate weakness, severe weakness
or inability to perform the test (complete loss) [22].
Straight Leg Raise (SLR) Testing
Electromyography
Standard surface electromyography (EMG) electrodes
were placed over the soleus, medial gastrocnemius, tibia-
lis anterior, vastus medialis, rectus femoris, semitendino-
sus, biceps femoris, and gluteus maximus muscles of the
right lower extremity [12]. Skin preparation and location
of electrode placement was in accordance with the sur-
face electromyography for non-invasive assessment of
muscles (SENIAM) guidelines [28]. A single reference
electrode was placed over the ipsilateral patella. Each
subject performed three repetitions of maximal volun-
tary isometric muscle contractions (MVC) for 5 seconds
each for purposes of EMG signal normalization
[12,29,30]. Manual resistance was provided by the tester
with the subject in supine and the limb stabilized imme-
diately proximal to the joint being tested. Instructions
were given to either push or pull against the examiner’s
resistance and to not let the examiner move the limb.
The calf musculature was tested in a neutral ankle posi-
tion, the quadriceps and hamstrings were tested with
the knee in approximately 30° flexion, and the gluteal
musculature was tested in approximately neutral hip
position [12,29,30]. EMG signals were acquired with a
bandwidth frequency of 50-500 Hz and amplified
(2000×) at a sampling rate of 2000 Hz using a TeleMyo
900 System, NorBNC and an A/D USB converter using
MRXP Master Package software, Version 1.06.21 (Nor-
axon USA Inc., Scottsdale, AZ).
Goniometry
Twin-axis electrogoniometers (Noraxon USA Inc,
Scottsdale, AZ) were used to measure sagittal and coro-
nal plane movement of the right hip and knee [12]. The
goniometers were placed laterally over the joint line
aligned with the subject’s proximal and distal segments
for both the hip and knee. Goniometers were held in
place with double-sided tape and custom made neo-
prene straps. Coronal plane motions for the hip and
sagittal plane motions for the knee were used to confirm
that neutral hip abduction and adduction and full knee
extension were maintained during SLR testing. Subjects
utilized a custom-built hand held electronic button (trig-
ger) held in their dominant hand to indicate timing of
symptoms at start, onset of symptoms (P1) and maxi-
mally tolerated symptoms (P2) [12]. Data from these
devices were acquired at 2000 Hz and synchronized
with the EMG data using the NorBNC and A/D USB
converter (Noraxon USA Inc., Scottsdale, AZ).
Test procedure
Straight leg raise (SLR) neurodynamic testing methodol-
ogy has been described [12]. In brief, the subject was
positioned in supine with standardized head support.
Additional pillows were provided if requested. The sub-
ject’s right ankle was placed in an APU® PRAFO® ankle
brace with outrigger bar and extra straps (Anatomical
Concepts, Inc, Poland, Ohio) to maintain a fixed ankle
position in either plantar flexion (30°) for the base SLR
test (PF/SLR) or in neutral (0°) dorsiflexion for the “sen-
sitized” SLR test (DF/SLR) [12]. One instructional trial
was performed on the left lower extremity prior to test-
ing the right lower extremity. Testing on the right extre-
mity included a total of 4 SLR tests, with 2 trials,
assigned in a random order, for each ankle position.
The tester placed the subject’sk n e ei nf u l le x t e n s i o n
(defined as end range resistance) and the subject was
instructed to indicate this start position (START) by
pressing the hand held trigger. Maintaining this knee
position, the subject’s hip was moved passively into flex-
ion at a rate of approximately 3°/sec while manually
avoiding hip rotation, abduction, or adduction. During
this passive hip flexion movement, the subject pressed
the hand held trigger to identify the moment they first
felt the onset of ANY symptoms (P1) and when their
symptoms became too intense to continue and they felt
they could not tolerate any further movement (P2). The
SLR test was stopped at P2 and this position was held
for 5 seconds before the limb was returned to resting on
the plinth. Two-minute rests were given between each
SLR trial. Subjects were asked to report their symptoms
including location, intensity, and quality at each of these
time points; START, P1, P2, and after 2 minutes rest.
Data processing
Mean voltage for EMG and degrees for hip range of
motion were obtained for a 100 msec window centered
on each of the following 4 time points; relaxed pre-test-
ing, START, P1, and P2. Raw EMG signals were con-
verted using a root mean squared (RMS) formula with a
50 msec interval and then normalized using the average
from the center 3-second window of the three trials of
MVC testing (presented as %MVC) [12,30]. A “triggered
muscle response” was defined as an increase in EMG
activity (expressed as %MVC) of at least a 1.5 fold above
resting levels in the “relaxed pre-testing” position taken
lying supine prior to establishing the START position
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from START position to P2.
Laboratory Testing
Subjects underwent a blood draw at the General Clinical
Research Center at UCSF. Blood samples were sent to
Quest Diagnostics, Inc (San Jose, CA) for hemoglobin
A1c (HbA1c) and mean plasma glucose (MPG) analysis.
These laboratory tests estimate average blood glucose
levels over the preceding 2-3 months.
Statistical Analysis
SPSS software, version 16.0 (SPSS Inc, Chicago, IL) was
used to perform all statistical analyses. Descriptive sta-
tistics were used to describe the means ± standard
deviations (SD) for all variables except frequency
descriptive statistics for symptom quality and location,
which are reported as percentages. Repeated measures
reliability analysis included intraclass correlation coeffi-
cients (ICC 3,1) including 95% confidence intervals
(lower bound, higher bound). Relationships between
demographic, clinical measures and SLR testing vari-
ables were assessed using Pearson correlation coeffi-
cients. Repeated measures general linear models were
used for within test differences between the START, P1
and P2 positions for EMG and ROM data. Paired t-tests
were used for between test comparisons (DF/SLR to PF/
SLR). One-way ANOVA was used to determine the
influence of DSP measures on EMG and ROM data
using subgroups defined by severity of neuropathy. Sub-
groups were based on the bilateral averaged VPT (VPT-
A V G ) :G r o u p1 )n os i g n so fD S P :0 - 1 5V ;G r o u p2 )
s i g n so fm i l dD S P :> 1 5 - 2 5V ;G r o u p3 )s i g n so fm o d e r -
ate DSP: >25-50 V; and Group 4) signs of severe DSP:
>50 V. The thresholds for Groups 1-3 are based on the
relative risk of developing foot ulcerations as outlined in
a literature review by Garrow and Boulton [9]. Group 4
is based on the finding that there is a more severe level
of DSP unique from the other groups that can be char-
acterized as individuals unable to feel the vibration of
the biothesiometer at the 50 V ceiling measurement
[25]. Symptom intensity was tested with non-parametric
statistics, including Kruskal-Wallis tests for independent
comparisons and Friedman’s test for related compari-
sons due to non-normal distributions. Alpha was set at
0.05.
Results
The sample of people with T2DM (n = 43) consisted of
21 females and 22 males with an average age of 56.3 ±
11.1 (range 21-75) years. Demographic information and
clinical examinations of signs of neuropathy included
VPT, MNSIc, and MDNS are provided in Table 1.
Vibration perception thresholds (VPT) repeated
measures reliability (ICC) was 0.97 (95% CI, 0.96, 0.98).
Mean MNSIc scores of 3.9 ± 2.4 exceeded the ≥2 cutoff
for identifying DSP [31], and mean MDNS of 13.8 ± 8.7
exceeded the >6 cutoff for identifying DSP [22]. Sub-
group analysis showed that MDNS scores extended over
the range of severity of DSP (p < 0.001). Specifically,
those individuals with signs of severe DSP had the high-
est scores on the MDNS (22.4 ± 8.3) compared to indi-
viduals with no signs of DSP (4.6 ± 5.0, p < 0.001),
individuals with signs of mild DSP (8.8 ± 4.4, p < 0.001)
and individuals with signs of moderate DSP (16.5 ± 5.8,
p = 0.023).
Correlations between assessment tools and demo-
graphic data are presented in Table 1. The three clinical
measurement tools used to identify signs of DSP (VPT,
MDNS, MNSIc) were highly correlated (>0.70 correla-
tion coefficient). The strongest such correlations were
between MDNS and MNSIc (0.82, p < 0.0005) and
between MDNS and VPT-AVG (0.76, p < 0.0005). Sub-
groups correlated with age (0.59, p < 0.001), MDNS
score (0.74, p < 0.001), MNSIc score (0.69, p < 0.001).
Age had a high correlation with VPT-AVG (0.57, p <
0.0005) but did not correlate with maximal hip flexion
ROM at P2 for PF/SLR (-0.14, p = 0.370).
The clinical questionnaires for symptoms related to
neuropathy (MNSIq) and activity level (Modified Baecke
questionnaire) are presented in Table 1. Further analysis
revealed that there were no differences between MNSIq
scores amongst subgroups (p = 0.480). The Modified
Baecke questionnaire work, sports and leisure subscales
and the total score did not vary amongst subgroups (p =
0.659, p = 0.347, p = 0.516, p = 0.324, respectively).
From the BPI-SF, the reported average pain rating (Q5)
was 3.0 ± 2.6 on a 0-10 point scale. The reported pain
“right now” (Q6) was 1.9 ± 2.2 on a 0-10 point scale.
Subgroup analysis revealed that there was no difference
in Q5 ratings (p = 0.894) or Q6 ratings (p = 0.762)
between subgroups.
Straight leg raise neurodynamic testing
The average speed of hip flexion during PF/SLR was 2.3
± 1.2°/second and DF/SLR was 2.1 ± 1.2°/second (p =
0.002). Amongst the participants, 23.3% did not request
any extra head support, 65.1% requested 1 pillow, 9.3%
requested 2 pillows and 2.3% requested 3 pillows during
the SLR testing. The number of pillows did not affect
the hip range of motion for either DF/SLR or PF/SLR at
either P1 or P2 (p = 0.55-0.94).
Range of motion
ICCs for hip flexion range of motion (ROM) between
trials were 0.90 (95% CI, 0.82, 0.94) for PF/SLR at P1,
0.94 (95% CI, 0.90, 0.97) for PF/SLR at P2, 0.89 (95%
CI, 0.80, 0.94) for DF/SLR at P1 and 0.96 (95% CI, 0.92,
0.98) for DF/SLR at P2. The hip range of motion to P1
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tion for both DF/SLR and PF/SLR (p < 0.0005) (Figure
1A). There was 4.3° ± 6.5° less hip flexion ROM at P1
during DF/SLR compared to PF/SLR (P1diff) (p < 0.001)
(Figure 1A). At P2 there was 5.4 ± 4.9° less hip flexion
ROM during DF/SLR compared to PF/SLR (P2diff) (p <
0.0005) (Figure 1A).
Further analysis revealed no effect of subgroup on hip
flexion range of motion for the P1diff measure. How-
ever, those individuals with signs of severe DSP had no
statistical difference in hip flexion ROM between PF/
SLR and DF/SLR tests (1.4° ± 4.2°; paired t-test p =
0.34). There was a significant effect of subgroup on the
difference in hip flexion ROM between PF/SLR and DF/
SLR at P2 (P2diff, p = 0.005) (Figure 2). The P2diff mea-
sure was 0.9° ± 2.5° in individuals with signs of severe
DSP compared to 6.6° ± 4.7° in the remainder of the
participants (all other subgroups combined). The eta
value for VPT-AVG subgroups was 0.53 with an eta
2 of
0.28, which indicates that subgroup explains 28% of the
variability in the P2diff outcome measure. There was
1.9° ± 4.5° more hip abduction at P2 during PF/SLR
compared to DF/SLR (p = 0.008). There were no differ-
ences in hip abduction at P1 between PF/SLR and DF/
SLR, nor in knee extension or valgus at either P1 or P2
(p = 0.13-0.96, data not shown).
Muscle activation
Muscle activity during SLR testing is presented in Table
2. Using the conservative threshold of 1.5-fold increase
over resting levels, no muscle activity was triggered at
the START position, P1 or P2 during PF/SLR. The addi-
tion of ankle dorsiflexion created a small change in the
pattern of muscle activation. During the DF/SLR, activ-
ity in the tibialis anterior was triggered when the limb
was placed in the START position when the ankle was
held in 0° dorsiflexion and the knee was held in full
extension. The mean increase in activity was almost a 2-
fold increase over resting levels from 5.3 ± 4.1%MVC to
9.7 ± 8.9%MVC. This increased activity was then stable
through the remainder of the DF/SLR testing and did
not change further when the limb was moved to P1 or
to P2.
Table 1 Demographic, clinical measures and correlations
Demographics Correlations
Subgroup Age BMI HbA1c MDNS MNSIc MNSIq VPT-
AVG
ModBaecke
Subgroup ——— 0.59* -0.08 0.08 0.74* 0.69* 0.19 0.92* -0.18
Age (years) 56.3 ± 11.1 0.59* ——— 0.08 -0.08 0.29 0.43* -0.06 0.58* 0.01
Height (m) 1.7 ± 0.1
Weight (kg) 94.0 ± 18.3
BMI 32.8 ± 6.6 -0.08 0.08 ——— 0.43* 0.04 0.35* 0.36* -0.06 -0.28
Duration of T2DM (years) 7.0 ± 7.7
Gender 49% female/51%
male
HbA1c 7.4 ± 1.8 0.08 -0.08 0.43* ——— 0.24 0.35 0.28 0.12 -0.57*
Vibration perception threshold
(VPT)
Right halluces (volts) 30.1 ± 14.8
Left halluces (volts) 29.9 ± 15.6
VPT-AVG for bilateral halluces (volts) 30.0 ± 14.9 0.92* 0.58* -0.06 0.12 0.75* 0.71* 0.27 ——— -0.20
MNSIq (0-13) 3.8 ± 2.4 0.19 -0.06 0.36* 0.28 0.39* 0.57* ——— 0.27 -0.34*
MNSIc (0-10) 3.9 ± 2.4 0.69* 0.43* 0.35* 0.35 0.80* ——— 0.57* 0.71* -0.28
MDNS (0-46) 13.8 ± 8.7 0.74* 0.29 0.04 0.24 ——— 0.80* 0.39* 0.75* -0.19
ModBaecke Questionnaire
Work subscale 2.5 ± 0.5
Sports subscale 2.7 ± 1.1
Leisure subscale 2.7 ± 0.5
Total score 7.9 ± 1.7 -0.18 0.01 -0.28 -0.57* -0.19 -0.28 -0.34* -0.20 ———
Abbreviations: Body mass index (BMI), hemoglobin A1c (HbA1c), Michigan diabetic neuropathy score (MDNS), Michigan neuropathy screening instrument -
clinical portion (MNSIc), Michigan neuropathy screening instrument - questionnaire portion (MNSIq), Vibration perception threshold averaged for right and left
halluces (VPT-AVG), and the Modified Baecke questionnaire total score (ModBaecke).
Pearson product correlations are presented with significance set at p < 0.05 (*)
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higher tibialis anterior muscle activation at the START
position during DF/SLR compared to PF/SLR (p <
0.001) (Table 2). Interestingly, there was a simultaneous
decrease in muscle activation in the vastus medialis and
biceps femoris (p < 0.001 and p = 0.032). At P1, there
was a significantly higher activation in the tibialis ante-
rior and soleus during DF/SLR compared to PF/SLR
(p < 0.001 and p = 0.033). A similar pattern was also
present at P2, where there was a significantly higher
activation of tibialis anterior during DF/SLR compared
to PF/SLR (p = 0.001). Further analyses of muscle activ-
ity showed that there was no subgroup effect on muscle
activity at any time point; START, P1, or P2.
Symptom intensity
The mean symptom intensity at the START position
was 0.7 ± 1.4 during PF/SLR (Figure 1B). The symptom
intensity increased to 2.8 ± 1.7 at P1 and to 6.8 ± 2.0 at
P2 during the PF/SLR (p < 0.001 both). During DF/SLR
the mean intensity went from 0.8 ± 1.5 at the START
p o s i t i o nt o3 . 0±1 . 8a tP 1a n dt o6 . 8±2 . 0a tP 2( p<
0.001 both). The mean intensity at P1 was significantly
higher by 0.3 ± 0.8 points during DF/SLR compared to
PF/SLR (p = 0.043). There was no difference in mean
intensity between PF/SLR and DF/SLR at the START
position, P2 or rest after SLR. Further analyses revealed
no subgroup effect on symptom intensity during PF/SLR
or DF/SLR at either P1 or P2.
Figure 1 Range of motion and symptom intensity during SLR neurodynamic testing. Straight leg raise neurodynamic test results are
presented for hip flexion range of motion in degrees (A) and symptom intensity (0-10 scale) (B). Gray dotted lined body diagrams represents
the PF/SLR test and black lined body diagrams represent the DF/SLR test. Significance is indicated by an * and was set at p < 0.05. A) Hip
flexion to the onset of symptoms (P1) and to the maximally tolerated position (P2) is significantly greater than the zeroed START position (p <
0.05). The differences between the PF/SLR and the DF/SLR are 4.3° at P1 and 5.4° at P2 (p < 0.05). B) Symptom intensity on a 0-10 point scale is
presented for each SLR. The gray dotted line represents the PF/SLR test and the black line represents the DF/SLR test. START position is full
manual knee extension prior to hip flexion while supine lying. P1 represents the moment of first onset of symptoms or the first increase above
resting symptoms and P2 represents the maximally tolerated symptom position. Symptom intensity is significantly increased at both P1 and P2
over START position values (p < 0.05). There was 0.3-point significantly greater symptom intensity at P1 when in the DF/SLR test compared to
the PF/SLR test.
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The frequencies of symptom locations reported at the
START, P1 and P2 during SLR are presented in Figure
3. More than 15% of subjects reported symptoms in
both the dorsal and plantar surfaces of bilateral feet at
the START position for both PF/SLR and DF/SLR
(Figure 3A &3D). During PF/SLR at P1 and P2, the
most frequent symptom location was reported in the
right posterior thigh followed by the right posterior leg
(Figure 3B &3C). A similar pattern was seen during DF/
Figure 2 Impact of DSP severity subgroups on difference in range of motion between SLR tests. The difference in hip flexion range of
motion between PF/SLR and DF/SLR at the maximally tolerated symptom position (P2) is presented on the Y-axis (P2diff) in degrees. Subgroups
are presented on the X-axis and include the following subgroups based on bilateral averaged VPT (VPT-AVG); 1) no signs of DSP: 0-15 V, 2) signs
of mild DSP: >15-25 V, 3) signs of moderate DSP: >25-50 V, and 4) signs of severe DSP: >50 V. Individuals with signs of severe DSP had a
significantly lower P2diff compared to two of the other subgroups. Significance is indicated by an * and was set at p ≤ 0.05.
Table 2 Muscle activation pattern (%MVC) during SLR neurodynamic testing
PF/SLR DF/SLR
Muscle Resting Start P1 P2 Start P1 P2
Soleus 20.2 ± 16.1 19.9 ± 15.7 21.3 ± 16.6† 21.7 ± 16.3 20.7 ± 17.4 23.0 ± 19.5† 22.6 ± 16.7
Medial gastrocnemius 14.6 ± 13.6 16.0 ± 15.2 18.9 ± 19.3 20.2 ± 21.5 16.8 ± 16.2 19.4 ± 20.77 19.9 ± 18.0
Tibialis anterior 5.3 ± 4.1 5.2 ± 4.3† 5.7 ± 5.5† 6.3 ± 6.9† 9.7 ± 8.9 *† 9.0 ± 8.0 *† 9.4 ± 10.1 *†
Vastus medialis 13.8 ± 12.2 13.9 ± 12.9† 16.3 ± 14.9 16.5 ± 14.0 9.9 ± 7.6† 15.7 ± 14.1 15.6 ± 12.9
Rectus femoris 11.8 ± 7.8 12.4 ± 10.1 14.8 ± 14.7 15.9 ± 13.1† 12.6 ± 9.7 13.4 ± 9.9 14.2 ± 9.6†
Semitendinosus 9.3 ± 8.3 9.7 ± 9.0 10.6 ± 9.0 12.4 ± 9.1 9.6 ± 9.5 11.3 ± 9.5 12.7 ± 9.9
Biceps femoris 9.3 ± 6.1 10.4 ± 7.1† 11.2 ± 7.9 13.5 ± 8.8 9.1 ± 6.3† 13.3 ± 17.4 13.4 ± 9.4
Gluteus maximus 28.4 ± 21.0 28.2 ± 23.3 31.6 ± 26.9 36.0 ± 29.2 28.8 ± 22.6 34.8 ± 43.8 38.9 ± 36.1
* denotes statistically significant increase of greater than 1.5x “Resting” levels for general linear model of repeated measures for within test differences.
† denotes statistically significant difference between PF/SLR and DF/SLR tests using paired t-test comparison for “Start” and “P1” and “P2.”
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Page 7 of 14Figure 3 Reported symptom locations during SLR neurodynamic testing. Body chart representations are presented for frequencies of
symptom location reported during SLR testing. A, B, C represents PF/SLR at the START, onset of symptoms (P1) and the maximally tolerated
position (P2), respectively. D, E, F represents DF/SLR at the START, onset of symptoms (P1) and the maximally tolerated position (P2),
respectively. Frequencies are reported in 10% intervals from a white color of 0% frequency to 90-100% as dark red (see key in center of figure).
There were >15% bilateral symptoms in the feet at the START position for both PF/SLR and DF/SLR. There were more frequent right posterior
leg symptoms in the DF/SLR test when compared to the PF/SLR at P2.
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Page 8 of 14SLR, including the right posterior thigh being the most
frequent symptom location at P1 and P2, followed by
the right posterior leg (Figure 3E &3F). During PF/SLR,
there was a 7.0% increase in the frequency of reported
symptoms in the right plantar foot while there was an
18.6% increase frequency of symptoms reported in the
right posterior hip at P2 compared to the START posi-
tion. During DF/SLR, there was no change in the fre-
quency of right plantar foot symptoms while there was
an 18.6% increase frequency of symptoms reported in
the right posterior hip at P2 compared to the START
position.
With the addition of ankle dorsiflexion (DF/SLR) there
was an increase in the frequency of reported movement
induced symptoms (not present at START position) at
P1 by 16.2% in the posterior thigh compared to PF/SLR.
However, the addition of ankle dorsiflexion only
increased the frequency of movement induced symp-
toms by 2.3% in the posterior leg and reduced the fre-
quency of movement induced symptoms by 2.3% in
plantar surface of the foot. When taken to P2, the addi-
tion of ankle dorsiflexion increased the frequency of
movement induced symptoms in the posterior thigh by
4.6% and the posterior leg by 16.3%, while there was a
reduction in movement induced symptoms in the plan-
tar surface of the foot by 7.0%
Symptom quality
Frequencies of symptom descriptions are presented in
Figure 4. Symptoms reported in <10% of participants are
not presented. At the START position 58.1% of the sub-
jects reported no symptoms during PF/SLR (Figure 4A).
The main symptom reported in the START position dur-
ing PF/SLR was tingling (14.0%). When taken to P1, the
additional symptom of stretch was most commonly
reported, followed by tightness/tension, then pain, and
finally numbness (Figure 4B). When taken to P2, pain
frequency increased by 9.3% and burning was reported in
14.0% of the subjects (Figure 4C). In contrast, 48.8% of
subjects reported no symptoms at the START position
during DF/SLR (Figure 4D). Numbness and tingling were
present in 18.6% at the START position during DF/SLR
with an additional 11.6% reporting tension/tightness (Fig-
ure 4D). When DF/SLR was taken to P1 there was a simi-
lar response to PF/SLR where stretch was the most
common symptom reported, followed by tightness/ten-
sion, and then pain (Figure 4E). When taken to P2 during
DF/SLR, the frequency of pain and numbness increased
by 7% and 4.6% (Figure 4F).
Between test comparisons revealed that there was only
a 2.3% increase in reported pain at P1 during the DF/
SLR compared to the PF/SLR and no difference (0%) at
P2. There were no differences greater than 5% in fre-
quency of reported stretch, tightness/tension, numbness,
tingling between DF/SLR and PF/SLR tests at either P1
or P2 with the one exception being a 7.0% increase in
the frequency of reported stretch at P2 during DF/SLR
compared to PF/SLR. Further analysis revealed that in
individuals with signs of severe DSP, 44.4% (4/9)
reported parasthesias (numbness, tingling, pins/needles)
at rest prior to beginning testing and 55.6% (5/9)
reported them during SLR testing. Of the four subjects
that reported paraesthsias at rest, all reported them in
bilateral dorsal and plantar surfaces of their feet and
these symptoms were unchanged during testing.
Discussion
We found that mechanosensitivity in the lower extre-
mity is present in people with T2DM when evaluated
through clinical neurodynamic testing. However, many
of the outcome measures utilized in neurodynamic test-
ing, including changes in hip flexion range of motion
with addition of ankle dorsiflexion, symptom location
and muscle activity, differed in people with T2DM when
compared with previous findings in people without
T2DM. Importantly, some of the signs and symptoms
that present with the sensitizing maneuver of ankle dor-
siflexion were not present in individuals with T2DM
with signs of severe neuropathy.
The magnitude of impact that the addition of ankle
dorsiflexion has on hip flexion range of motion during
SLR testing may reflect the state of mechanosensitivity
of the neural structures being tested. Mechanosensitivity
is a normal protective response to the stresses applied
to nerves during limb movement. Thus, it is reasonable
to expect hip flexion range of motion to be reduced
when a SLR is performed with the ankle in a position of
dorsiflexion. The addition of dorsiflexion has been
shown to induce longitudinal gliding and increased
strain in the lower extremity posterior neural structures,
providing a “sensitized” version of the SLR [32-34]. In
previous studies of healthy individuals, the addition of
dorsiflexion to the SLR resulted in between 5.5° and
10.1° reduction in SLR angle depending on the test end-
point [12,16]. In people with T2DM we found that the
addition of ankle dorsiflexion caused a normal 4° reduc-
tion in hip flexion range of motion when tested to P1,
but only a 5° reduction when tested to P2. This repre-
sents a statistically significant 50% reduction in the
effect of dorsiflexion on hip flexion range of motion in
people with T2DM compared to people without T2DM
when tested to P2 (p = 0.039) [12]. Moreover, in indivi-
duals with T2DM and severe DSP the addition of dorsi-
flexion did not alter hip flexion range of motion at P1
or P2. This represents statistically significant 90% reduc-
tions in the effect of dorsiflexion on hip flexion in peo-
ple with T2DM with severe DSP when tested to P2
compared to people without T2DM (p = 0.001) [12].
The diminished response to the “sensitized” SLR in
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Page 9 of 14Figure 4 Reported symptom quality descriptors during SLR neurodynamic testing. Histograms are presented for frequencies of symptom
quality reported during SLR testing. A, B, C represents PF/SLR at the START, onset of symptoms (P1), and maximally tolerated position (P2),
respectively. D, E, F represents DF/SLR at the START, onset of symptoms (P1), and maximally tolerated position (P2), respectively. Symptoms
reported in <10% of participants are not presented. The frequency of no symptoms at the START position was greater in the PF/SLR compared
to the DF/SLR. The most common symptoms at the START position were numbness and tingling. Stretch and tightness/tension were the two
most frequent reported symptoms at P1 and P2 during both SLR tests. Pain was also induced in >20% of the subjects at P1 and >30% of the
subjects at P2 during both SLR tests.
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Page 10 of 14people with T2DM and severe DSP may reflect a
reduced protective response to neural loading during
limb movements due to a diminished mechanosensitivity
of the lower extremity nervous system.
A comparison to findings in healthy controls in a pre-
vious study demonstrates that our sample of people
with T2DM had reduced general flexibility during SLR
[12]. Specifically, during the SLR with the least load on
the nervous system (PF/SLR), people with T2DM had
54.3° ± 21.5° of hip flexion ROM, significantly less than
the 67.6° ± 22.1° documented in the same test in healthy
individuals without T2DM (p = 0.027) [12]. These find-
ings are in agreement with studies that have documen-
ted reduced range of motion in both ankle and hip
joints in people with T2DM compared to healthy indivi-
duals without DM [35-37]. To our knowledge, our study
is the first to document a reduction in available hip
range of motion during SLR testing in people with
T2DM. Further studies are warranted to examine the
mechanisms behind proximal mobility changes in people
with T2DM.
The absence of triggered muscle activation found in
t h ep r e s e n ts t u d yi np e o p l ew i t hT 2 D Mi sd r a s t i c a l l y
different from that found previously in healthy indivi-
duals without T2DM. In the present study we found
only the tibialis anterior became activated during the
DF/SLR as defined by a 1.5× increase over resting EMG
activity. In comparison, a previous study of healthy indi-
viduals without T2DM found muscle activation using
this same threshold criteria during the PF/SLR in the
rectus femoris at P1 and in the soleus, medial gastrocne-
mius, tibialis anterior, vastus medialis, rectus femoris,
biceps femoris, and gluteus maximus at P2 [12]. This
study also found activation of the soleus, tibialis ante-
rior, vastus medialis, and semitendinosis muscles during
DF/SLR at P1 and the soleus, medial gastrocnemius,
tibialis anterior, vastus medialis, rectus femoris, and
semitendinosis at P2 [12]. People with T2DM did not
exhibit the co-contraction of anterior and posterior limb
muscles that was evident in healthy controls at P1 in
the sensitized DF/SLR.
Our sample of individuals with T2DM had much
higher resting muscle activity in comparison to pre-
viously reported healthy individuals without T2DM [12].
It is possible that this apparent higher resting muscle
activity is a MVC calculation artifact due to a reduction
in contraction effort during MVC procedures either due
to true strength deficits or to the presence of resting
symptoms. Since resting activity is converted into a %
M V C ,t h ev a l u e so fm u s c l ea c t i v i t ya tr e s tw o u l db e
higher if the effort during MVC testing was reduced
because of the presence of pain. The authors speculate
that reduced muscle output during MVC testing due to
resting symptoms, contributed to the findings of higher
resting activity in our studyw h e ne x p r e s s e da s% M V C .
One possible explanation for the activation of the tibialis
anterior is related to the START position for this DF/
SLR test which included fixation in a customized brace.
Since the increase in tibialis anterior activity was trig-
gered during dorsiflexion positioning and then remained
stable during SLR to P1 or P2, we hypothesize that the
brace itself provided pressure or proprioceptive feedback
to the participant that created a responsive increase in
muscle tone in the tibialis anterior. Further investigation
is necessary to elucidate if this finding is clinically
important and to understand why this was not observed
in the posterior leg musculature.
Reliance solely on muscle activity measures for deci-
sive conclusions for mechanosensitivity is not reasonable
due to the high variability of this type of measurement.
Some individuals had no muscle activation during SLR
testing at P1 and P2, which is consistent with previous
study findings [38,39]. In our present study, 12.2% of
the people with T2DM had no muscle activity at P2
during PF/SLR compared to 10.0% of healthy individuals
without T2DM in our previous study [12]. Comparisons
during DF/SLR showed that 14.6% of the people with
T 2 D Mh a dn om u s c l ea c t i v i t ya tP 2c o m p a r e dt o5 . 0 %
of healthy individuals without T2DM in our previous
study [12].
Symptom quality, intensity and distribution differed in
people with T2DM when compared to healthy indivi-
duals without T2DM [12]. At the START position, peo-
ple with T2DM frequently reported symptoms
associated with neurogenic sources, such as numbness
and tingling, which were not present in healthy indivi-
duals. During limb movement, people with T2DM
reported pain (>20% at P1 and >30% at P2) more fre-
quently than healthy individuals (≤10%). Furthermore,
the subgroup of people with signs of severe DSP
reported symptoms associated with neurogenic sources,
such as numbness and tingling 55.6% of the time and
pain 33.3% of the time during SLR testing. The intensity
of symptoms reported in people with T2DM during DF/
SLR and PF/SLR tests was 0.3 points higher on a 0-10
point numeric pain rating scale at P1. Although this is
statistically significant it does not represent a clinically
meaningful difference between tests [40]. People with
T2DM reported more symptoms at the START position
than those without T2DM. The percentage of people
with T2DM with symptoms in the START position dur-
ing PF/SLR testing was 41.9% and during DF/SLR was
51.2%. In comparison, the percentage of healthy indivi-
duals without T2DM with symptoms in the START
position was 15.0% during PF/SLR and 25.0% during
DF/SLR. Lastly, in contrast to healthy controls, people
with T2DM reported symptoms on the dorsal and
plantar surfaces of bilateral feet in the START position
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Page 11 of 14(16-30%) [12]. In healthy individuals without T2DM, fre-
quency of symptoms in the posterior hip was at most
10% compared to 27.9% in people with T2DM, with the
most dramatic difference occurring at P2.
In the subgroup of individuals with T2DM and severe
DSP we found symptoms and clinical examination signs
that were consistent with recent findings examining
pain presentation phenotypes in neuropathic pain condi-
tions [41]. Scholz et al. determined eight specific pat-
terns of signs and symptoms of which they found
people with DSP presented with three of these patterns
[41]. These three patterns had multiple characteristics in
common that relate to our findings, including ongoing
pain, dysesthesia (primarily tingling and numbness),
reduced response to monofilament, pinprick and vibra-
tion testing and the absence of a response to passive
movement evoked pain and an absent response to
straight leg raise testing [41]. These characteristics
match the cluster of symptoms and physical signs iden-
tified in our study sample, particularly those with signs
of severe DSP.
A mechanism that would explain the reduction of
mechanosensitivity seen in people with T2DM and DSP
has yet to be established. A recent study documented an
altered ratio of mechanoresponsive to mechanoinsensi-
tive C-fibers in people with diabetes and mild DSP in
the common fibular nerve at the knee level [42]. It was
found that the ratio of 2:1 mechanoresponsive:mechan-
oinsensitive C-fibers in healthy controls without DM or
neuropathy was reversed to 1:2 in subjects with DM and
mild DSP. The shift appeared to occur simultaneously
with a general reduction of C-fibers. The authors con-
cluded that changes in small fiber health associated with
DSP leads to an impairment of mechanoresponsive
nocioceptors. Although the ratio of mechanoresponsive
to mechanoinsensitive C-fibers is unknown in our popu-
lation of individuals with T2DM and DSP, altered
microneurographic findings would be consistent with
the decrease in mechanosensitivity during the SLR tests
that we found in this population.
One major limitation of our study is the small sample
size reducing the power to detect differences between
variables with smaller effect sizes and diminishing the
ability to extrapolate findings to larger populations. A
potential covariate in our study is the impact of age on
peripheral nerve health. We attempted to match our
sample mean age to previous studies of peripheral nerve
health in people with T2DM and studies of SLR neuro-
dynamic testing to allow for valid comparisons. In our
study we found no correlation between age and any hip
flexion range of motion measure during SLR testing, in
agreement with a previous study of age and hamstring
length [43]. The average age of our study participants
closely resembles larger studies including studies by
Fedele et al. examining prevalence in 8757 people in
I t a l yw i t hT 2 D M( a g e=5 5 . 8±1 0 . 4 )a n db yR a h m a ne t
al. examining multiple clinical measures of neuropathy
(age = 63.0 ± 7.8) [10,26]. In our study sex was not sta-
tistically associated with any hip flexion range of motion
outcome measure, although a larger investigation with
differing methodology found that women have greater
hip range of motion during SLR testing [43].
An additional limitation is the difference of hip abduc-
tion range of motion at P2 during PF/SLR compared to
DF/SLR which could have influenced the SLR outcome
measures. The mean difference was less than 2° between
the PF/SLR and DF/SLR and is not likely clinically sig-
nificant but still represents a potential confounding vari-
able that should be acknowledged in the interpretation
of our study findings. Precisely controlled standardized
procedures for clinical neurodynamic testing, as were
utilized in this study, are warranted to minimize tester
induced variability.
One characteristic difference between our present
findings and that of SLR neurodynamic test findings in
healthy individuals without T2DM is body mass index
(BMI). The body mass index was larger in our sample of
people with T2DM (32.8 ± 6.6 kg/m
2)c o m p a r e dt o
healthy individuals without T2DM (25.9 ± 8.8 kg/m
2,p
= 0.001) [12]. Mean weight in the people with T2DM
was also greater in the present study (94.0 ± 18.3 kg)
compared to the healthy individuals without T2DM
(71.2 ± 24.8 kg, p < 0.001) [12]. Height was not different
between these two study samples (p = 0.127) [12]. We
did not find a correlation between BMI in people with
T2DM and hip flexion range of motion during SLR. We
did not measure nutritional deficits in our study such as
vitamin B12 deficiencies which may be a potential con-
founding variable. Future studies should investigate neu-
rodynamic testing in stratified BMI groups, BMI
matched groups and vitamin B12 deficiencies to further
explore the effects of body mass and nutritional status
on mechanosensitivity of peripheral nerves.
Our study supports specific considerations for patient
education and therapeutic exercise instructions. Altera-
tions or avoidance of activities that involve cumulative
loading of the nervous system via multiple joints should
be considered in people with T2DM and signs of DSP.
This could include avoiding movements into slumped
postures with the feet elevated, altering specific activities
of daily living such as forward bending to tie one’s
shoes, or avoiding specific movements or postures
assumed during recreational activities such as yoga or
Pilates. An understanding of the health of the nervous
system including the ability to respond to and protect
against over stretch should be incorporated into clinical
decision making for physical examination, exercise pre-
scription and patient education in people with T2DM.
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Page 12 of 14Although this study only examined passive limb posi-
tioning for short duration, it provides evidence to help
support our clinical decisions related to protection of
the peripheral nervous system in people with T2DM
and DSP.
Conclusions
We have provided evidence that the normal protective
responses to neural loading during neurodynamic test-
ing may be diminished in people with T2DM particu-
larly those with signs of severe DSP. Additionally, we
found increased frequency of resting symptoms in peo-
ple with T2DM and increased frequency of reported
neurogenic related symptom qualities during SLR test-
ing. We found the addition of ankle dorsiflexion does
not induce the same degree of reduction of hip flexion
range of motion and the same pattern of muscle protec-
tive guarding during SLR testing in people with T2DM.
The findings of our study call into question the clinical
decision of performing neurodynamic testing on people
with signs of severe DSP. Without the ability to respond
to the increases in neural loading associated with neuro-
dynamic testing and sensitizing maneuvers, this popula-
tion is at risk for injury from testing and the
information gathered will be of limited use to the clini-
cian. It is recommended that clinicians perform a simple
screen of sensation such as vibration perception testing
or the MDNS prior to considering the appropriateness
of neurodynamic assessments.
When considering testing in people with T2DM, it is
important to understand the global impact on mechano-
sensitivity due to the common distal symmetrical
polyneuropathy associated with T2DM. When neurody-
namic testing is deemed appropriate in this population,
additional considerations are necessary for test interpre-
tation in people with T2DM. It is paramount to clearly
establish the person’s resting symptoms prior to
performing SLR testing. Symptoms that are normally
associated with neurogenic sources may be present
bilaterally at rest confounding SLR test interpretation in
people with T2DM. Consideration of specific movement
induced symptoms in addition to symptoms present at
rest should assist the clinician interpret neurodynamic
testing appropriately. Previous recommendations have
included utilizing the onset of symptoms (P1) or the
increase above resting symptoms as the end point of the
SLR neurodynamic test [12,44]. The findings of our
study support using this same end point for SLR testing
in people with T2DM to avoid potential harm of over
stressing the nervous system [12].
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